ESR1 and breast carcinoma: In contrast, tumors harboring the estrogen receptor have been shown to promote a T helper2 (Th2) pro-tumorigenic immune environment and to downregulate MHC class II expression in breast cancer cells [44,45], thus leading to a weaker immune response.